Integra LifeSciences (NASDAQ:IART) Downgraded by Zacks Research to “Strong Sell”

Integra LifeSciences (NASDAQ:IART) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Monday, Zacks reports.

A number of other equities analysts have also issued reports on the stock. BMO Capital Markets reiterated a “market perform” rating and set a $14.00 target price (down from $15.00) on shares of Integra LifeSciences in a research report on Thursday, October 22nd. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Monday. Wells Fargo & Company set a $13.00 price target on shares of Integra LifeSciences and gave the company an “equal weight” rating in a report on Thursday, October 22nd. Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Citigroup restated an “outperform” rating on shares of Integra LifeSciences in a research report on Thursday, October 22nd. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Reduce” and a consensus price target of $16.12.

Integra LifeSciences Stock Down 0.9%

Shares of NASDAQ IART opened at $11.99 on Monday. The firm’s 50-day simple moving average is $15.11 and its 200 day simple moving average is $14.10. The company has a market cap of $932.50 million, a price-to-earnings ratio of 70.53 and a beta of 1.21. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.49.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.03. The company had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same quarter in the previous year, the business posted ($0.07) EPS. On average, equities analysts expect that Integra LifeSciences will post 2.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in shares of Integra LifeSciences in the 2nd quarter worth $82,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Integra LifeSciences during the second quarter worth $84,000. Sequoia Financial Advisors LLC increased its holdings in Integra LifeSciences by 27.4% in the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 3,059 shares during the last quarter. Amundi increased its holdings in Integra LifeSciences by 80.8% in the first quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after purchasing an additional 8,681 shares during the last quarter. Finally, State of Wyoming increased its holdings in Integra LifeSciences by 26.4% in the first quarter. State of Wyoming now owns 25,276 shares of the life sciences company’s stock valued at $238,000 after purchasing an additional 5,278 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.